As of the end of fiscal year 2024, Tracenable has captured detailed data on Regeneron Pharmaceuticals's corporate ownership structure, providing a comprehensive view of its downstream entities and the role within the broader group hierarchy.a
The dataset includes information on 32 affiliated entities, encompassing subsidiaries, joint ventures, associates, and other related companies in which Regeneron Pharmaceuticals holds an equity interest or exercises control as the ultimate parent.a
Tracenable's data also records effective ownership percentages that Regeneron Pharmaceuticals holds across these entities, providing transparency into its corporate control, ownership hierarchy, and group governance practices.a
| Entity Name | Country | Type | Ownership | LEI | PermID |
|---|---|---|---|---|---|
Checkmate Pharmaceuticals, Inc.a | USA | Subsidiary | Not Specified | ||
Decibel Therapeutics, Inc.a | USA | Subsidiary | Not Specified | ||
Eastside Campus Holdings LLCa | USA | Subsidiary | Not Specified | ||
Loop Road Holdings LLCa | USA | Subsidiary | Not Specified | ||
Old Saw Mill Holdings LLCa | USA | Subsidiary | Not Specified | ||
OSMR Holdingsa | BMU | Subsidiary | Not Specified | ||
Oxular Acquisitions Limiteda | GBR | Subsidiary | Not Specified | ||
Oxular Inc.a | USA | Subsidiary | Not Specified | ||
Oxular Limiteda | GBR | Subsidiary | Not Specified | ||
Regeneron Assurance, Inc.a | USA | Subsidiary | Not Specified | ||
Regeneron Atlantic Holdingsa | BMU | Subsidiary | Not Specified | ||
Regeneron Austria GmbHa | AUT | Subsidiary | Not Specified | ||
| 0000000 | 0000000 | 0000000 | 0000000 | 0000000 | 0000000 |
| 0000000 | 0000000 | 0000000 | 0000000 | 0000000 | 0000000 |
| Showing 12 out of 32 entities. Get complete coverage in the full dataset. | |||||
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
Tracenable's dataset provides geographic insights into Regeneron Pharmaceuticals's group entities, revealing where its subsidiaries, joint ventures, associates, and affiliates are located worldwide.a
In total, the Regeneron Pharmaceuticals group consists of 31 entities distributed across 15 countries, reflecting the company's global footprint and jurisdictional presence.a
This visualization highlights the geographical distribution of Regeneron Pharmaceuticals's corporate structure, helping assess its international exposure, operational reach, and cross-border governance landscape.a
In 2024, Tracenable identified that the Regeneron Pharmaceuticals group consisted of 31 entities operating across 15 countries.a
This indicates a moderate geographic diversification, reflecting Regeneron Pharmaceuticals's expansion strategy, global footprint, and cross-border exposure.a
Regeneron Pharmaceuticals's subsidiaries and affiliates are primarily concentrated in North America and Europe, which host 93.75% of its total entities.a
This regional distribution suggests that Regeneron Pharmaceuticals's operational and financial activities are centered in these markets, either due to core business operations, supply chain proximity, or favorable regulatory environments.
Regeneron Pharmaceuticals shows a moderate to high level of transparency regarding its ownership structure.
The disclosure includes information on subsidiaries, joint ventures, and associates, allowing partial visibility into the company's downstream relationships and areas of shared control.a
While not a full edge-level disclosure, the data still provides meaningful insight into Regeneron Pharmaceuticals's governance framework and group composition, positioning it among more transparent reporters in its industry.
Yes. Tracenable's data shows that 2 entities (6.25%) are registered in jurisdictions commonly classified as low-tax or offshore financial centers, such as Bermuda.a
This may indicate tax optimization strategies or the use of special-purpose vehicles (SPVs) within Regeneron Pharmaceuticals's ownership structure.